The first ADC approved for previously treated metastatic HER2-mutant NSCLC, trastuzumab deruxtecan, combines an anti-HER2 monoclonal antibody (trastuzumab) linked to a topoisomerase I inhibitor (deruxtecan). Here, ERBB2 is linked to non-small cell lung carcinoma.